New and improved, Johnson & Johnson’s Caplyta significantly improved remission rates

Johnson & Johnson’s Caplyta significantly improved remission rates in major depressive disorder when used with antidepressants, as highlighted at a major neuropsychopharmacology meeting.

Johnson & Johnson’s Caplyta, when used adjunctively with antidepressants, nearly doubled six-week remission rates in major depressive disorder in data presented at a leading neuropsychopharmacology meeting.

Meanwhile, Johnson & Johnson’s launch of the Arbrea Breast Simulator Surgeon App for Mentor in the U.S. introduces augmented-reality-based pre-operative planning that allows personalized visualization of breast-augmentation outcomes.